Context: Mutations in the steroidogenic acute regulatory protein (StAR) gene often cause lipoid congenital adrenal hyperplasia (LCAH). In this disorder an impairment of steroid synthesis leads to adrenal and gonadal insufficiencies with a particular female genital phenotype in both human karyotypes. Pregnancy in LCAH has not been yet reported.
Objective: We describe the first cases of pregnancy in a LCAH female patient bearing the L275P mutation in the StAR gene.
Design: We studied the gonadal function, pubertal development, and apply the appropriate hormonal therapy to support pregnancies.
Patient: A 46,xx patient of French Canadian descent was diagnosed with LCAH at the age of 4.5 months. Substitution therapy with glucocorticoids and mineralocorticoids led to normal growth and development. Progressive pubertal development started at the age of 11 7/12 yr. Menarche occurred at 14 2/12 yr with normal regular menstruations thereafter but without ovulation.
Results: Clomiphene stimulation induced the first pregnancy at 25 4/12 yr of age. Spontaneous abortion occurred after 6 wk gestation. The second pregnancy (with clomiphene stimulation) was induced at the age of 26 yr. Progesterone (Prog) therapy was added at the 17th day of the cycle to protect pregnancy. Vaginal delivery of dichorionic-diamniotic twin pregnancy occurred at 30 wk gestation (two normal weight male babies). Two years later, again under clomiphene stimulation, she underwent another successful singleton pregnancy and delivered a normal weight female baby at 36 wk. The pregnancies were almost uncomplicated.
Conclusion: Despite the dysfunctional StAR, pregnancy is possible under the proper therapeutic strategy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1210/jc.2008-1694 | DOI Listing |
JBRA Assist Reprod
December 2024
Department of Reproductive Endocrinology, Oasis India, Banjara Hills Road No 2, Hyderabad - 500034, India.
Objective: To compare the efficacy and safety of PPOS and CPOS in high-responder patients undergoing COS for IVF.
Methods: This one-year prospective, randomized, controlled trial included 86 high-responder patients. They were divided into PPOS (n=44) and CPOS (n=42).
Int J Fertil Steril
October 2024
Department of Obstetrics and Gynecology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.Email:
Background: The role of laparoscopy and hysteroscopy in managing unexplained infertility (UI) is debatable because of the improved success rate of assisted reproductive technologies (ART). This study aims to assess the findings of laparoscopy and hysteroscopy in selected women diagnosed with UI to determine the frequency of such pathological conditions in order to manage them properly.
Materials And Methods: The current cross-sectional study was conducted on 96 women who attended an infertility clinic at the educational hospitals of Isfahan University of Medical Sciences from March 2018 to February 2020.
Fertil Steril
November 2024
Department of Public Health and Primary Care, University of Leuven, Leuven, Belgium; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.
Diagnostics (Basel)
October 2024
Kayseri Acıbadem Hospital IVF-Unit, Kayseri 38030, Turkey.
Objectives: To determine the effect of short-term metformin administration on follicular fluid (FF) total oxidant status (TOS), total antioxidant status (TAS), oxidative stress index (OSI) and nuclear factor kappa B (NF-kB) in women with clomiphene citrate-resistant polycystic ovary syndrome (PCOS).
Methods: Fifty-eight patients aged 23-34 who were planned to have intracytoplasmic sperm injection due to clomiphene citrate-resistant PCOS were included in the study. Participants were divided into two groups according to whether they used metformin or not.
Contracept Reprod Med
October 2024
Department of Obstetrics and Gynaecology, Faculty of Medicine and Pharmacy, University of Kisangani, Kisangani, Democratic Republic of the Congo.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!